Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
The authors of this review discuss the evidence regarding early treatments for Parkinson’s and how they compare in terms of efficacy and side effects, and when symptomatic treatment should be started. They conclude with implications for both clinical practice and future research.
Source:
The Lancet Neurology
SPS commentary:
A related Comment discusses clinical use of levodopa and monoamine oxidase B inhibitors, and the factors that should be considered when deciding when to initiate treatment. It notes the lack of evidence for any effect of the drugs on neurodegeneration, and how in the most part they do not address the non-motor aspects – two of the most important unmet needs in Parkinson's disease.